Factor 8 Ehl denied for missing prior authorization by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for factor 8 ehl are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denied Your Extended Half-Life Factor VIII — Prior Authorization Required

Extended half-life (EHL) Factor VIII products are specialty biologics used to prevent and treat bleeding in hemophilia A. Because of their cost, UnitedHealthcare requires advance prior authorization (PA) before it will cover them. A denial for "prior authorization required" means the prescription was dispensed or billed before UHC approved it — or the PA request was submitted but is still pending or was administratively closed. This denial is not a judgment about whether the drug is appropriate for you; it is a process gate.

## Why This Denial Is Appealable

If the PA was never submitted, work with your prescriber and specialty pharmacy to submit it immediately. If a PA was submitted and denied on clinical grounds, or if the drug was dispensed urgently without time to obtain PA, you have strong grounds to appeal. Courts and regulators have consistently held that retrospective denials for urgent or emergency medications — where delay would have caused serious harm — can be overturned on appeal.

## Federal Appeal Framework

• Internal appeal: Submit within 180 days of the denial. For ongoing therapy that cannot be interrupted, request a concurrent expedited review. UHC must respond to expedited appeals within 72 hours.
• External review (ACA §2719): After exhausting internal appeal, you may request independent external review. The window is generally four months from the final internal denial. The external reviewer is not affiliated with UHC.
• ERISA §503: Employer-sponsored plan members are entitled to a full-and-fair review, including access to the specific clinical criteria applied.
• State insurance department: If UHC does not respond within required timeframes, file a complaint with your state's insurance commissioner.

## Documentation to Gather

1. Prescriber's PA request and any UHC correspondence — obtain copies of what was submitted and any response, including reference numbers. 2. Medical necessity letter — a detailed letter from your hematologist or hemophilia treatment center (HTC) documenting hemophilia A diagnosis, severity, bleeding history, and the clinical rationale for EHL formulation over standard half-life Factor VIII. 3. Infusion history — records of prior Factor VIII use, frequency of bleeds, adherence, and any issues with standard half-life products (e.g., breakthrough bleeds, vein access challenges, adherence burden). 4. Urgency documentation — if the drug was dispensed without PA due to an acute bleed or clinical urgency, a same-day clinical note documenting the emergency. 5. UHC's published coverage policy — download the current medical/coverage policy for Factor VIII products from UHC's provider portal and confirm your case meets each listed criterion.

## Criteria-Mapping Structure

Build a point-by-point response to UHC's PA criteria: - Column A: Each criterion from UHC's published medical/coverage policy (copy the exact text). - Column B: The chart fact, lab value, or clinical note that satisfies that criterion, with the document name and date.

For a prior-auth appeal, also address timeliness: explain when the drug was needed, whether the clinical situation was urgent, and whether any delay in submitting the PA was due to circumstances beyond the patient's control. Attach all supporting documents as numbered exhibits.